Shots:

• The first patients have been dosed in the P-III study to evaluate the efficacy and safety of ARVN001 in macular edema associated with uveitis (UME) in China
• The results from the P-III PEACHTREE study showed a good efficacy & safety profile of ARVN001, improvement in vision, reduction of edema, lower or comparable AE rates of IOP raising & cataract for patients treated with ARVN001 for 24wks.
• In Sep 2021, ARVN001 has received approval for 2nd indication from the CFDA for DME & the company plans to start the P-I trial in China shortly. In Mar 2020, the company has acquired an exclusive license for the development & commercialization of Xipere in Greater China & South Korea

Click here to­ read full press release

Ref: PR Newswire | Image: Arctic